Possible mechanism of the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, in diabetic rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 3, 2012, Pages 334-340

  Singh, Kulwinder ^a   Sharma, Kuldeepak ^a   Singh, Manjeet ^a   Sharma, P L ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

A 779; AVE 0991; diabetes mellitus; lipids; Mas receptor

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7] RECEPTOR MAS; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; CREATININE; GLUCOSE; LIPID; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE METABOLISM; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; HEMODYNAMIC PARAMETERS; HYPERGLYCEMIA; HYPERTENSION; ISOLATED HEART; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPID METABOLISM; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEINURIA; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPECTROPHOTOMETER; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

EID: 84865618226     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311435534     Document Type: Article

References (37)

1. Kannel WB, Hjortland M, Castellim WP.. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974 ; 34: 29-34
2. Dhalla NS, Liu X, Panagia V, et al. Subcellular remodelling and heart dysfunction in chronic diabetes. Cardiovasc Res. 1998 ; 40: 239-247 (Pubitemid 28506032)
3. Dronavalli S, Duka I, Babris GL.. The pathogenesis of diabetic nephropathy. Nat Clin Prac Endocrinol Metab. 2008 ; 4: 444-452
4. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000 ; 87: E1 - E9
5. Santos RA, Campagnole-Santos MJ, Andrade SP.. Angiotensin-(1-7): an update. Regul Pept. 2000 ; 91: 45-62
6. Pinheiro SV, Simoes e, Silva AC, Sampaio WO, et al. Nonpeptide AVE-0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004 ; 44: 490-496 (Pubitemid 39281501)
7. Ferreira AJ, Santos RAS. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res. 2005 ; 38: 499-507 (Pubitemid 40703878)
8. Singh T, Singh K, Sharma PL.. Ameliorative potential of angiotensin1-7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats. Meth Find Exp Clin Pharmacol. 2010 ; 32: 19-25
9. Grobe JL, Der L, Sarkissian S, et al. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond). 2007 ; 113: 357-364 (Pubitemid 47572276)
10. Santos RAS, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor Mas knockout mice. Hypertension. 2006 ; 47: 996-1002 (Pubitemid 44297574)
11. Yamada K, Iyer SN, Chappell MC, et al. Converting enzyme determines plasma clearance of angiotensin (1-7). Hypertension. 1998 ; 32: 496-502 (Pubitemid 28429139)
12. Wiemer G, Dobrucki LW, Louka FR, et al. AVE-0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002 ; 40: 847-852 (Pubitemid 35434905)
13. Benter IF, Yousif MHM, Anim JT, et al. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2007 ; 292: H666 - H672
14. Singh K, Singh T, Sharma PL.. Beneficial effects of angiotensin (1-7) in diabetic rats with cardiomyopathy. Ther Adv Cardiovas Dis. 2011 ; 5: 159-167
15. Al-Maghrebi M, Benter IF, Diz DI.. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res. 2009 ; 59: 263-268
16. Trinder P.. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969 ; 6: 24-25
17. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974 ; 20: 470-475
18. Folch J, Lees M, Sloane-Stanley GH.. A simple method for isolation and purification of total lipids from animal tissue. J Biol Chem. 1956 ; 226: 497-509
19. Deepa PR, Varalakshmi P.. Beneficial cardio-renovascular effects of low-molecular-weight heparin-derivative on adriamycin-induced glycosaminoglycanuria and tissue lipid abnormalities. Toxicology. 2005 ; 211: 77-85 (Pubitemid 40603628)
20. Cho BHS. Improved enzymatic determination of total cholesterol in tissues. Clin Chem. 1983 ; 29: 166-168 (Pubitemid 13167646)
21. Bonsnes RW, Taussky HH.. On the colorimetric determination of creatinine by the Jaffe reaction. J Biol Chem. 1945 ; 158: 581-591
22. Shargel L, Wu-Pong S, Yu ABC Applied biopharmaceutics and pharmacokinetics. New Delhi: McGraw Hill ; 2005: 678-683.
23. Fawcett JK, Scott JE.. A rapid and precise method for the determination of urea. J Clin Pathol. 1960 ; 13: 156-159
24. Watanabe N, Kamei S, Ohkubo A, et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem. 1986 ; 32: 1551-1554 (Pubitemid 17027779)
25. Chang S, Kim Y, Lee H, et al. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension. 2009 ; 54: 591-597
26. Keane WF.. The role of lipids in renal disease: Future challenges. Kidney Int. 2000 ; 57: S27 - S31
27. Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003 ; 100: 1226-1231 (Pubitemid 36183984)
28. Jayasooria AP, Mathai ML, Walker LL, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci U S A. 2008 ; 105: 6531-6536 (Pubitemid 351754541)
29. Santos SH, Braga JF, Mario EG, et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol. 2010 ; 30: 953-961
30. Dhaunsi GS, Yousif MHM, Akhtar S, et al. Angiotensin (1-7) prevents diabetes-induced attenuation in PPAR-γ and catalase activities. Eur J Pharmacol. 2010 ; 638: 108-114
31. Walter T, Balschum D, Voigit JP, et al. Sustined long-term potentiation and anxiety in mice lacking the Mas protoncogene. J Biol Chem. 1998 ; 273: 11867-11873
32. Sampaio WO, Santos RAS, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007 ; 49: 185-192 (Pubitemid 46360359)
33. Lemos VS, Silva DM, Walther T, et al. The endothelium-dependent vasodilator effect of the nonpeptide Ang-(1-7) mimic AVE-0991 is abolished in the aorta of Mas-knockout mice. J Cardiovasc Pharmacol. 2005 ; 46: 274-279 (Pubitemid 41262828)
34. Ruggenenti P, Mise N, Pisoni R, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation. 2003 ; 107: 586-592 (Pubitemid 36176809)
35. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001 ; 286: 421-426 (Pubitemid 32681484)
36. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001 ; 134: 629-636 (Pubitemid 32322240)
37. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003 ; 63: 225-232 (Pubitemid 35463925)